Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPLAR: Atezolizumab vs Docetaxel in NSCLC
NCT01903993Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2013
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Overall Survival up to 28 months. Started Aug 2013; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01903993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01903993.